A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma

2024-513439-25-00 Protocol 87562761MMY1001 Human pharmacology (Phase I) - First administration to humans Ended

Start 30 Apr 2025 · End 22 May 2026 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol 87562761MMY1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 80
Countries 1
Sites 5

Relapsed/Refractory Multiple Myeloma

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Apr 2025 → 22 May 2026
Decision date (initial)
2024-10-11
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/Refractory Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 15 5
Rest of world
Australia, Taiwan, Canada, Korea, Democratic People's Republic of
65

Investigational sites

Spain

5 sites · Ended
Clinica Universidad De Navarra
Ensayos Clínicos de Hematología, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitario De Salamanca
Ensayos Clinicos de Hematología, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Universitario Fundacion Jimenez Diaz
Unidad de Ensayos Fase I, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Institut Catala D'oncologia
Hemarología, Carretera Canyet S/n, 08916, Badalona
Hospital Clinic De Barcelona
Hematología, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-04-30 2026-05-22 2025-04-30 2026-05-04

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-19 Spain Acceptable
2024-10-11
2024-10-11
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-19 Spain Acceptable
2025-02-24
2025-02-24
3 SUBSTANTIAL MODIFICATION SM-2 2025-10-20 Spain Acceptable
2025-12-09
2025-12-11